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Antibiotic resistance carries a fitness cost that must be overcome in order for
resistance to persist over the long term. Compensatory mutations that
recover the functional defects associated with resistance mutations have
been argued to play a key role in overcoming the cost of resistance, but com-
pensatory mutations are expected to be rare relative to generally beneficial
mutations that increase fitness, irrespective of antibiotic resistance. Given
this asymmetry, population genetics theory predicts that populations
should adapt by compensatory mutations when the cost of resistance is
large, whereas generally beneficial mutations should drive adaptation
when the cost of resistance is small. We tested this prediction by determining
the genomic mechanisms underpinning adaptation to antibiotic-free
conditions in populations of the pathogenic bacterium Pseudomonas
aeruginosa that carry costly antibiotic resistance mutations. Whole-genome
sequencing revealed that populations founded by high-cost rifampicin-
resistant mutants adapted via compensatory mutations in three genes
of the RNA polymerase core enzyme, whereas populations founded by
low-cost mutants adapted by generally beneficial mutations, predominantly
in the quorum-sensing transcriptional regulator gene lasR. Even though the
importance of compensatory evolution in maintaining resistance has been
widely recognized, our study shows that the roles of general adaptation in
maintaining resistance should not be underestimated and highlights the
need to understand how selection at other sites in the genome influences
the dynamics of resistance alleles in clinical settings.
1. Introduction
The evolution of antibiotic resistance in pathogenic bacteria is typically
accompanied by fitness costs that are expressed in terms of reduced growth
rate, competitive ability and virulence [1–3]. Fitness costs generate selection
against resistance when pathogen populations encounter antibiotic-free
environments, as occurs during transmission between hosts or when antibiotic
use is discontinued. Because exposure to high doses of antibiotic is transient,
resistance will only be maintained in the long term if resistant populations
can evolve adaptations that offset the cost of resistance. Therefore, understand-
ing the mechanisms that allow resistant bacterial populations to evolve
increased fitness is of fundamental importance to understanding the long-term
maintenance of resistance in pathogenic bacteria.
One possible mechanism through which bacteria can overcome the cost of
resistance is by acquiring compensatory mutations that reduce or eliminate
the fitness costs associated with resistance alleles by recovering the functional
defects associated with resistance mutations [4–9]. Alternatively, it is possible
for antibiotic-resistant populations to overcome the fitness cost of resistance
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Figure 1. Adaptation to the cost of rifampicin resistance. This figure shows the competitive fitness (mean+ s.e; n ¼ 3) of the eight rpoB mutants used to found
the selection experiments (blue diamonds) and the average fitness of three endpoint populations (red squares) evolved from each rpoB mutant. The rpoB mutations
carried by the rifampicin-resistant mutants are specified in the names assigned to the mutants. The relative fitness of all endpoint populations converged towards
that of the rifampicin-sensitive ancestral strain (standardized to a value of 1). In all cases, the average relative fitness of the endpoint populations showed a
significant increase compared with that of the initial rpoB mutant (two-sample t-test, p, 0.05).
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ness without offsetting the cost of resistance per se. Unlike
compensatory mutations, generally beneficial mutations con-
tribute to an increase in fitness, regardless of the genetic
background in which they arise [10,11]. In this scenario,
resistant populations overcome the cost of resistance by
adapting to general environmental conditions, such as nutri-
ent availability and the presence of stressors. The dominant
view that has emerged from studies of the long-term evolution
of antibiotic-resistant populations is that adaptation to the cost
of resistance is driven by compensatorymutations [1,2,12–14].
Compensatory mutations have been identified in clinical
pathogen populations, especially Mycobacterium tuberculosis
[15–17], and compensatory adaptation has emerged as a cen-
tral explanation for the long-term maintenance of resistance
in pathogen populations [3].
Although compensatory mutations have been identified
in a wide range of systems, the fact that resistant populations
can also evolve by generally beneficial mutations that
increase fitness, irrespective of antibiotic resistance, is far
less frequently mentioned in current discussions of antibiotic
resistance evolution. It has been estimated that there are, on
average, 12 possible compensatory mutations per deleterious
mutation in bacteria [18], and the rate of compensatory
mutation should therefore be in the order of 12 sites per
genome x 9  10211 mutations per site per generation
under laboratory conditions [19], which corresponds to
1  1029 per genome per generation. On the other hand,
generally beneficial mutations have been estimated to occur
at a rate between 1  1028 and 1  1025 per genome per gen-
eration under laboratory conditions, which is 10–10 000
times higher than our crude estimate of the rate of compensa-
tory mutation [20–23]. This asymmetry suggests that, all else
being equal, generally beneficial mutations are expected to
contribute more towards adaptation in antibiotic-resistant
populations than compensatory mutations do.
However, adaptation in asexual populations is driven by
a small minority of mutations with relatively large benefits
that overcome stochastic drift and competition from rival
beneficial mutations owing to clonal interference [20,22,24,25].
Compensatory mutations are therefore expected to make a dis-
proportionately large contribution to adaptation when they areassociated with large fitness benefits relative to generally ben-
eficial mutations. Because compensatory adaptation directly
recovers the functional defects associated with resistance
mutations [5,7,8,26], compensatory mutations should confer
large fitness benefits in populations carrying very costly resist-
ance mutations. However, the fitness benefits associated with
compensatory mutations are expected to be small in popu-
lations carrying low-cost mutations. This population genetic
framework predicts that the likelihood of adaptation by com-
pensatory mutations should increase with the cost of
resistance [27]. Crucially, studies of evolution in antibiotic-
resistant populations have largely focused on adaptation in
populations that carry very costly resistance mutations
[6,28–32]. We postulate that the roles played by general
adaptation in eliminating the fitness cost of antibiotic
resistance are greater than currently thought.
To test the hypothesis that high fitness costs promote evol-
ution by compensatory adaptation, we allowed populations of
eight isogenic rifampicin-resistant isolates of the opportunistic
pathogen Pseudomonas aeruginosa that carry different fitness
costs, as well as their rifampicin-sensitive ancestor, to evolve
for 300 generations in an antibiotic-free rich medium. Extensive
whole-genome sequencing was used to systematically identify
compensatory mutations and generally beneficial mutations in
evolved endpoint populations.2. Results and discussion
(a) Evolved rifampicin-resistant mutants recover
from the fitness cost of resistance
To study adaptation to the cost of rifampicin resistance, we
allowed three independently propagated populations of
eight different rifampicin-resistant rpoB mutants that carried
different fitness costs to evolve in a rifampicin-free culture
medium for 300 generations. Fitness varied considerably
between the rifampicin-resistant mutants that were used to
initiate the selection experiment (figure 1: one-way ANOVA,
F7,16¼ 4.66, p ¼ 0.0052). Fitness increased over the course of
the selection experiment (paired t-test, t7 ¼ 5.47, p ¼ 0.0009),
and the fitness of the evolved populations was very similar
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Figure 2. Targets of selection. In the frequency distribution of genes that acquired mutation(s) in at least two independently evolved endpoint populations, a high
degree of parallel evolution can be observed in both the rifampicin-resistant and control populations. At the same time, a distinct difference in the spectrum of
genes that were most frequently mutated can also be observed.
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resistant mutants were evolved from. These results clearly
demonstrate that selection in the absence of antibiotics can
rapidly eliminate the substantial fitness cost that is associated
with rifampicin resistance for a range of rpoB mutations.
(b) Testing for compensatory adaptation using whole-
genome sequencing
To determine the genetic basis of adaptation in antibiotic-
resistant populations, we performed whole-genome
sequencing on three randomly selected colonies isolated
from each evolved endpoint population (electronic sup-
plementary material, table S1: 8 mutants  3 populations per
mutant  3 isolates per population ¼ 72 isolates). As a control
experiment, we also sequenced the genomes of evolved
isolates from rifampicin-sensitive ancestral populations that
were evolved for the same number of generations (electronic
supplementary material, table S2: 12 populations 3 isolates
per population ¼ 36 isolates). Non-synonymous single-
nucleotide polymorphisms (SNPs) and short indel (insertion
and deletion) mutations of less than 1 kb in protein-coding
regions were the most common forms of mutations that we
identified. Silent and intergenic mutations were found at low
frequencies, as were large deletions and duplications spanning
more than one gene.
The mutations that we identified may include beneficial,
neutral or mildly deleterious mutations. Parallel evolution
provides a hallmark of genes that are under strong positive
selection [33–36], and we therefore focused our analysis
on genes in which we detected parallel evolution. In our
study, parallel evolution, in a particular gene, can be demon-
strated either by mutations in different populations or by
different mutations within the same endpoint population.
Our results broadly indicate that such parallel evolution
was very common in both the evolved resistant and control
populations. Among the resistant mutant populations
(figure 2), five genes contained 69% of all mutations that
were detected in the sequenced endpoint isolates evolved
from the rifampicin-resistant mutants (highlighted in blue),whereas five genes covered 75% of all mutations found in
the evolved control populations (highlighted in red).
Because compensatory mutations interact epistatically
with resistance mutations to recover fitness [26,31,37], we
expected compensatory mutations to be found in evolved
resistant populations, but not in rifampicin-sensitive ancestral
populations. Previous studies have shown that second-site
mutations in RNA polymerase subunits (rpoA, rpoB and
rpoC) can compensate for the cost of rifampicin resistance
[5,7,16,26]. Consistent with this, we found nine independently
evolved point mutations in these RNA polymerase genes
among the resistant populations, but no RNA polymerase
mutations were detected in the evolved control populations.
Interestingly, one of the rpoB mutations represents a reversion
mutation that swept to fixation in a population that was
initiated by the H531R mutant. The reversion mutation
restored the rifampicin-sensitive phenotype, which constitutes
an evolutionary reversal of antibiotic resistance. Several lines
of evidence suggest that the remaining RNA polymerase
mutations are compensatory mutations rather than generally
beneficial mutations. First, the intragenic second-site
mutations in rpoB found in this study (E528D, H531C and
N573S) are known to recover the reductions in transcriptional
efficiency and fitness costs associated with the original rpoB
mutations [5]. Second, we observed three independent
examples of parallel evolution in rpoB at an amino acid level.
An additional mutation in the same codon as the original
rpoB mutations H531R and H531Y can result in a common
amino acid substitution H531C, which was observed in two
populations founded by H531R and one population founded
by H531Y (electronic supplementary material, table S1).
H531C can offset the fitness cost of the original rpoBmutations
without altering the rifampicin resistance phenotype [38].
To test the hypothesis that low fitness costs constrain com-
pensatory adaptation, we tested for a negative correlation
between the frequencies of RNA polymerase mutations and
the initial cost associated with each rpoB mutation (figure 3).
In support of our hypothesis, we found a significant negative
correlation between the number of compensatory mutations
per genome and the initial cost associated with resistance
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Figure 3. High fitness costs drive compensatory adaptation in rifampicin-resistant populations of P. aeruginosa. This graph shows the number of compensatory
mutations in RNA polymerase per evolved isolate (mean+ s.e; n ¼ 3) as a function of fitness cost associated with the eight rifampicin resistance mutations
(mean+ s.e; n ¼ 3). We included the reversion mutation in this analysis, because it is an adaptation to the cost of rifampicin resistance. The mean number
of compensatory mutations per isolate increases with the cost of resistance, as judged by a Spearman’s rank-order correlation ( p, 0.05). (Online version in colour.)
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9.72, p ¼ 0.0206). Almost all isolates from populations that
were founded by very costly resistance mutants, such as
H531R and H531Y, carry compensatory mutations, whereas
no compensatory mutations were found in populations that
were founded by low-cost resistance mutations such as S536F.
(c) Adaptation in antibiotic-resistant populations is
dominated by generally beneficial mutations
Although we found evidence for compensatory adaptation
when the cost of resistance was large, the dominant genetic
mechanism of adaptation in antibiotic-resistant populations
was mutations in lasR, a key transcriptional regulator gene
involved in quorum-sensing [39,40]. About 71% of all endpoint
populations founded by resistant mutants had at least one
sequenced isolate with mutations in lasR. There was also a
high diversity of mutations in lasR, which include 26 indepen-
dently evolved SNPs and short indel mutations, as well as four
independent large deletions (more than 2 kb) affecting lasR and
adjacent genes. These mutations are thought to disrupt LasR
function and result in quorum-sensing deficiency [41–45]. For
example, the missense mutation A231V, which was observed
in two independent populations founded by the rpoB mutant
Q518R, is known to disrupt LasR functions and quorum-
sensing-regulated phenotypic traits [41]. Mutations in lasR led
to increased fitness in rpoB mutants (electronic supplementary
material, figure S1). In agreement with this, numerous studies
have shown that P. aeruginosa populations adapt to novel
environments through the loss of LasR function [42–46].
lasR mutations were also detected in the evolved control
populations (electronic supplementary material, table S2),
confirming that lasR mutations were not compensatory.
More specifically, three independent lasR mutations we
observed are known to compromise LasR function by elimi-
nating the start codon (M1I), deleting the lasR promoter
region [47] or preventing LasR multimer formation via the
P74L mutation [48]. However, the proportion of control
populations that had at least one sequenced isolate with
lasR mutations (33%) was lower compared with that of resist-
ant populations (71%), so it remains to be understood why
such discrepancies exist between the resistant and control
populations.(d) The evolutionary dynamics of general
and compensatory adaptation
To better understand the conflict between compensatory
adaptation and general adaptation, we studied the dynamics
of adaptation by sequencing a time series of isolates from a
subset of our selection lines. We focused on populations in
which both generally beneficial mutations and compensatory
mutations were identified (electronic supplementary material,
table S1). The co-occurrence of generally beneficial mutations
and compensatory mutations implies that these populations
are likely to provide direct insights into the outcome of compe-
tition between these two classes of beneficial mutations. Based
on the sequencing results, we constructed the evolutionary his-
tory for these four populations (figure 4). The key insight that
emerged from our phylogenetic inference was that general
adaptation tends to precede compensatory adaptation. In
three of the four populations, general adaptation initially
occurred through the spread of lasR mutations during the
first 24 days of the experiments (figure 4b–d). Successful
lasR mutants then acquired compensatory mutations in RNA
polymerase genes, which began to increase to detectable fre-
quency by the end of the experiment. In the H531Y-A
population (figure 4a), initial adaptation was dominated by
the spread of mutations in the gacA gene. GacS/GacA modu-
lates the expression of more than 500 genes of the RsmA
regulon and is indirectly involved in the regulation of
quorum-sensing [49–51]. Subsequently, isolates carrying com-
pensatory mutations in the rpoB gene also began to increase to
detectable frequency by day 30.
Several factors are likely to have favoured this repeatable
evolutionary dynamic of general adaptation followed by
compensatory adaptation. We detected a vast diversity of
lasR mutations, suggesting that any mutation which disrupts
LasR production and the quorum-sensing phenotype is
beneficial under these experimental conditions. By contrast,
we found a relatively small number of compensatory
mutations in RNA polymerase, which supports the idea that
compensatory mutations are rare [52]. This asymmetry is illus-
trated by the observation that the frequency of repeated
independent mutations in rpoB (3/7) was much higher than
that in lasR (1/30) among the resistant populations. lasR
mutations also confer large fitness benefits. For example,
gacA (Q168*)
PA4690a (K138N)
PA0625
(D17 bp)
H531Y (population A)
Q518R (population B)
Q518R (population C)
Q518L (population C)
genotype with generally
beneficial mutation(s) only
genotype with compensatory
mutation(s)
inferred genotype
acquisition of additional
mutation(s)
identical genotypes from
different time points
arnT (silent)
arnT (silent)
lasR (C201*)
arnT (silent)
lasR (Y112*)
fusA1(Y630C)
arnT (silent)
lasR (A231V)
rpoB(E528D) arnT (silent)
lasR (K16*)
rpoB (E528D)
arnT (silent)
lasR (D10 bp)
rpoB (Q193L)
arnT (silent)
lasR (V208E)
rpoC (D410G)
PA1428a (silent)
lasR (Q160*)
intergenic (SNP)
rpoB (E528D)
lasR (A231V)
rpoB (G367S)
lasR (R180W)
wzz (T50A)
arnT (silent)
lasR (Y112*)
rpoC (D410G)
arnT (silent)
lasR (Y112*)
PA1768 (193T)
arnT (silent)
lasR (K16*)
arnT (silent)
lasR (D10 bp)
arnT (silent)
lasR (Y112*)
arnT (silent)
lasR (A231T)
PA0716 (Y15C)
arnT (silent)
lasR (V208E)
PA1428a
(silent) lasR(D74 bp)
lasR (D1 bp)
wzz (T50A)
lasR
(Y64F)
lasR
(D1 bp)
PA1428a (silent)
lasR (Q160*)
lasR (R216W)
wzz (T50A)
lasR
(R216W)
lasR
(A231V)
day
18
24
30
day
18
24
30
day
18
24
30
day
18
24
30
lasR
(D1 bp)
PA1429, lasR, rsaL, lasl
(D3210 bp)
dnaX (+6 bp)
PA1429, lasR, rsaL, lasl
(D3210 bp)lasR
(D1 bp)
lasR (D1 bp)lasR (S129I)
lasR (D1 bp)
intergenic (+4 bp)
rpoA (S49F) 
PA1429, lasR, rsaL, lasl
(D3210 bp)
pqsE (C97Y)
rpoB (N573S)
PA1829 (I295T)
rpoB
(N573S)
gacA
(Q168*)
gacA (Q168*)
ftsY (+6 bP)
gacA (Q168*)
PA4690a (K138N)
gacS (D29 bp)
PA3133 (D1 bp)
PA1734
(R27L)
(b)(a)
(c) (d )
Figure 4. Clonal interference constrains compensatory adaptation. A schematic diagram representing the phylogeny inferred for six randomly selected isolates
sampled from the 18th, 24th and 30th (final) days for four populations in which the co-occurrence of generally beneficial mutations and compensatory mutations
was detected in the endpoint populations. Circles represent the observed genotypes, and the diameter of a circle indicates the frequency of that isolate in the
population (n ¼ 1, 2 or 3). Red circles denote isolates carrying compensatory mutations, while black circles denote isolates carrying generally beneficial mutations
but not compensatory mutations. Each thin arrow represents the acquisition of one or more additional mutations with respect to the previous genotype. Mutations
carried by individual isolates are shown in text, with newly acquired mutations in blue and previously acquired mutations in black.
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addition to their original rpoBmutations, showed an increased
fitness of between 15.6% and 32.3% (electronic supplementary
material, figure S1). This suggests that the fitness benefit
associated with lasR mutations was likely to be comparable
to, or greater than, the benefit associated with compensatory
mutations, except when the cost of resistance was very large.
Surprisingly, we found that the control populations often
carried mutations in genes that were not mutated in resistant
populations (figure 2), including wspA and wspF from the wsp
operon (n ¼ 9), dipA (n ¼ 12), as well as morA (n ¼ 2). The
absence ofwspA/wspF, dipA andmorAmutations in the resistant
populations raised the possibility that the fitness benefit con-
ferred by these mutations could be contingent on the absence
of rpoB mutations (sign epistasis) [53]. To test this hypothesis,
we measured the fitness of isolates carrying rpoB mutations
with dipA or morA mutations and found that dipA and morA
mutations were beneficial in the presence of rpoB mutations
[54], implying that sign epistasis cannot explain the absence of
mutations in these genes in the evolved resistant isolates. It is
conceivable that the different amounts of time spent by the var-
ious strains in the stationary phase could have contributed to
these differences in the mutational spectrum.3. Conclusion
The idea that compensatory adaptation eliminates the cost of
resistance and allows resistance alleles to effectively persist in
bacterial populations has been extensively studied inevolutionary models of antibiotic resistance [2,3,13,55–57].
Here, we examine the underlying genomic basis of adap-
tation in rifampicin-resistant populations of the pathogenic
bacterium P. aeruginosa. Although rifampicin-resistant popu-
lations quickly evolved to overcome their initial fitness
cost, compensatory mutations were fixed in populations
founded only by highly costly resistant mutants. Importantly,
many studies of evolution in antibiotic-resistant popula-
tions tend to focus on evolution in populations carrying
very costly resistance mutations [6,28–32]. Our results
suggest that the role of generally beneficial mutations in over-
coming the fitness cost of resistance may be more important
than currently thought. Given the functional diversity of
antibiotic resistance mechanisms, more insight into the con-
flicts between these two types of mutations could be
gleaned by performing experimental evolution studies
using antibiotic-resistant mutants that carry other types of
resistance mutations.
Although compensatory adaptation provides a more
direct solution to the cost of resistance, two constraints are
likely to restrict compensatory evolution. First, generally ben-
eficial mutations are more common than compensatory
mutations. While compensatory mutations usually occur in
the same protein or pathway as antibiotic resistance mutations
do [4,52], generally beneficial mutations are expected to occur
at many different sites in the genome. In our study, this asym-
metry is highlighted by the rarity of repeated independent
mutations in genes involved in general adaptation, notably
in lasR, versus the higher frequency of repeated nucleotide
substitutions in rpoB, which was involved in compensatory
rspb.royalsocietypublishing.org
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large effects on fitness that surpass those associated with com-
pensatory mutations (electronic supplementary material,
figure S1). We argue that compensatory adaptation tends to
occur when the cost of resistance is large, because compensa-
tory mutations provide very large fitness benefits in
populations carrying costly resistance mutations.
Given that the spread of compensatory mutations can be
delayed by the spread of generally beneficial mutations
owing to clonal interference, selection for compensatory adap-
tation will be relatively ineffective under conditions where
selection at other sites in the genome is strong. A number of
important selective forces are likely to exert strong and recur-
rent selective pressure on populations of bacterial pathogens,
such as antibiotic use [58,59], bacteriophage [60] and the
immune system [61], suggesting that compensatory adap-
tation may be difficult to acquire in clinical settings. These
constraints are probably especially important in opportunistic
pathogens, because they are essentially invading a novel niche
that imposes distinct selective pressures when they establish
infections in human hosts [35,62,63]. In this respect, it is inter-
esting to note that the best-characterized example of
compensatory adaptation in a clinical setting, rifampicin resist-
ance in M. tuberculosis [7,15,16], comes from an obligate
pathogen that is well adapted to life in human hosts [64].
Whole-genome sequencing is now being used extensively
to study the population biology of bacterial pathogens, and it
is often thought that mutations which are found in antibiotic-
resistant isolates are compensatory mutations [15,59,65–67].
Although there are some excellent examples of compensatory
adaptation in clinical pathogens [6,15,16,68–70], it is also
apparent that compensatory evolution is not ubiquitous
[57]. Our study highlights some of the obstacles to evolution
by compensatory mutations, but their consequences remain
unclear. On the one hand, it is possible that rapid adaptation
by generally beneficial mutations effectively eliminates selec-
tion against antibiotic-resistant pathogen lineages. In this
scenario, resistance alleles continue to carry a cost, but selec-
tion against resistant lineages is offset by the beneficial
mutations carried at other sites in the genome. Importantly,
antibiotic use results in a large increase in the population
size of antibiotic-resistant lineages, suggesting that they
should enjoy an increased likelihood of acquiring generally
beneficial mutations relative to sensitive strains that are sup-
pressed by antibiotic use. Compensatory mutations interact
epistatically with resistance mutations such that the loss of
resistance mutations becomes deleterious once compensatory
mutations have been acquired. By delaying the spread of
compensatory mutations, it is possible that generally
beneficial mutations increase the window of opportunity
for reversion to antibiotic sensitivity. It is hoped that future
work will shed light on the roles that selection for generally
beneficial mutation plays in the maintenance of resistance.4. Material and methods
(a) Selection experiment
The eight rifampicin-resistant rpoB mutants used in the selection
experiment were evolved from the rifampicin-sensitive
PAO1::mini-Tn7-pLAC-lux ancestral strain using a fluctuation
test [5]. All strains were streaked on M9KB agar plates [71] and
incubated overnight at 308C. On the next day, three independentcolonies per rpoB mutant strain were randomly selected for pro-
pagating three independent populations (denoted A–C) during
the selection experiment. About 1 ml of M9KB liquid culture
medium [71] was inoculated with a colony in the absence of
rifampicin. The bacterial cultures were incubated overnight
with shaking (225 r.p.m.) at 308C. On the next day, 1 ml of each
overnight culture was diluted 1000-fold in fresh M9KB medium
and incubated overnight under the same experimental conditions.
The serial transfer was repeated for 30 consecutive days, or
approximately 300 generations. Glycerol stocks of all populations
were prepared on the 18th, 24th and 30th (final) days of the selec-
tion experiment. In a separate set of control experiments, 12
independent colonies of the rifampicin-sensitive ancestral strain
were randomly selected for propagating 12 independent popu-
lations (denoted A–L) using the same experimental procedures
as described above.
(b) Competitive fitness assay
The competitive fitness of the endpoint populations of each
of the propagated populations was quantified relative to the
rifampicin-sensitive ancestral strain as previously described [5].
Briefly, overnight cultures of the endpoint populations, the
PAO1::mini-Tn7-pLAC-lux ancestral strain and a GFP-tagged
derivative strain of PAO1 were diluted 1 : 10 in M9KB medium
and regrown to early exponential phase at 308C with continuous
shaking (225 r.p.m.). Each non-fluorescent strain was mixed with
the GFP-tagged strain, diluted 200-fold in M9KB medium and
incubated in Nunc 96-well microplates (Thermo Scientific,
USA) at 308C overnight for approximately 24 h with continuous
shaking. The proportion of fluorescent and non-fluorescent cells
in each co-culture was determined using an Accuri C6 flow cyt-
ometer (BD Biosciences, USA) before and after the incubation.
The competitive fitness of each non-fluorescent strain was calcu-
lated as the ratio of population doublings of each endpoint
population relative to the GFP-tagged control strain it was com-
peting against [72]. The relative competitive fitness of the
endpoint populations was obtained by standardizing their com-
petitive fitness to that of the rifampicin-sensitive ancestral strain
within each set of competition experiments. Three biological and
three technical replicates of each strain were assayed for each
endpoint population.
To demonstrate that lasR mutations are beneficial under the
same conditions of the selection experiment, the competitive fit-
ness of three evolved rifampicin-resistant isolates that carried
different lasR mutations and the initial rpoB mutant strains was
determined relative to the rifampicin-sensitive ancestral strain
using a modified version of the competition assays, in which
all strains were regrown to exponential phase and co-cultured
overnight with the GFP-tagged control strain in 5 ml Falcon
tubes (BD Biosciences) using exactly the same growth conditions
as those under which the selection experiment was carried out.
(c) Whole-genome sequencing
The initial rpoB mutants and the endpoint populations of the
selection experiment were streaked on M9KB agar plates and
incubated overnight at 308C. On the next day, three colonies of
each population were randomly selected to inoculate M9KB
liquid medium incubated at 308C with shaking overnight. Geno-
mic DNA was extracted using the DNeasy Blood and Tissue Kit
(Qiagen, The Netherlands) according to the manufacturer’s pro-
tocol. The 12 initial isolates of the rifampicin-sensitive ancestral
strain and the three randomly selected colonies from the 12 end-
point populations, which were evolved from these initial isolates
during the control experiment, were prepared for whole-genome
sequencing using the same procedures.
To search for evidence of clonal interference in rpoB mutant
populations, six random isolates from the 18th and 24th days
rspb.royalsocietypublishing.org
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 on February 11, 2016http://rspb.royalsocietypublishing.org/Downloaded from of the selection experiment were selected for whole-genome
sequencing from four selected rpoB mutant populations
(H531Y-A, Q518L-C, Q518R-B and Q518R-C) using the same
procedures as described above. Three additional random isolates
from the four endpoint populations were whole-genome
sequenced to obtain a total of six isolates for each of the three
time points (excluding an isolate from the endpoint population
of Q518R-C, which was not successfully sequenced).
Paired-end whole-genome sequencing with read length of
100 bp was performed using the HiSeq 2000 sequencing system
(Illumina, USA). The average coverage was 44.1 (median cover-
age: 43.5). Variants were identified using an experimentally
validated in-house pipeline [72,73]. The initial rpoBmutant isolates
were found to have the same genetic background, with the excep-
tion of the specified mutations in rpoB. We discarded mutations
that were already present in all the initial isolates with respect to
the P. aeruginosa PAO1 reference genome, analysing only those
mutations that accumulated throughout the selection experiment.
(d) Statistics
All statistical analyses were performed using JMP software v. 11
(SAS, USA). Unless otherwise stated, all statistical tests aretwo-tailed, and the level of significance is 0.05. The degrees of
freedom are reported as subscripts next to the test statistics.Data accessibility. Whole-genome sequencing data are available at the
European Nucleotide Archive: http://www.ebi.ac.uk/ena/data/
view/PRJEB11978.
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